Navigation Links
TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development

Spotfire Platform Evolves with INTEGROMICS to Lead the Industry in Advancing Life Sciences Research, Discovery and Development

SOMERVILLE, Mass., Sept. 23 /PRNewswire-FirstCall/ -- TIBCO Software Inc. (Nasdaq: TIBX), together with INTEGROMICS, a provider of state-of-the-art software solutions for data management and data analysis in genomics, proteomics and drug discovery, today announced a solution for genomics research that provides researchers and scientists with a direct, interactive, visual approach to data analysis that rapidly reveals insights and unexpected relationships in genomics data.

Genomics technologies -- used by pharmaceutical R&D departments to understand disease biology and drug response in order to develop new and better drugs -- are now used across the entire drug development process to better understand disease biology, mechanisms of drug action, mechanisms of toxicity, and individuals and their response to a drug. Genomics-based biomarkers are dramatically impacting drug development by providing more precise diagnoses of disease states and drug response in individual patients. The software used to analyze and explore genomic data had not kept pace with the advancing genomics research. Spotfire and INTEGROMICS, however, joined forces to address the needs of modern genomics research in areas including biomarker research, translational medicine, and systems biology by introducing INTEGROMICS Biomarker Discovery for TIBCO Spotfire(R).

The scientific and workflow knowledge of INTEGROMICS, combined with the adaptability and ease of use of the TIBCO Spotfire platform, provide researchers with a powerful genomic data analysis environment. The new solution enables pharmaceutical, biotechnology, and academic research groups to quickly find and categorize complex patterns. With interactive analysis and high-impact visualization capabilities, researchers and scientists can examine the expression and annotation dimensions of their data and perform a variety of numerical analyses. Pharmaceutical companies can also use Spotfire(R) as a flexible analytics platform to allow them to combine and analyze new types of data in order to more quickly pursue their hypotheses and research strategies.

"Having developed microarray analytics for the last five years, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source," said Alberto Pasqual, vice president of R & D, INTEGROMICS. "With this set of tools, life science researchers can ask and answer new questions and create an advanced problem solving environment."

"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions and combining that information with other information about the genes to uncover information about the biology of disease and treatment," said Christian Marcazzo, senior director of Life Science Analytics for TIBCO Spotfire. "This solution helps researchers and scientists address one of the industry's long standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset."


INTEGROMICS, SL is a leading provider of IT solutions for life sciences (genomics and proteomics). It focuses on delivering products, services and training in two strategic areas: data management/integration and intelligent data analysis. The company has developed a network of collaborations both in industry and academia to provide complete technological solutions that will help our clients to achieve their goals. INTEGROMICS SL was founded in 2002 and is based in Granada, Spain, with offices in Madrid (Spain) and Philadelphia (USA). INTEGROMICS Inc. is a wholly owned subsidiary which was established in 2007. For more information:


TIBCO Software Inc. is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit

TIBCO, TIBCO Software, TIBCO Spotfire, and Spotfire are trademarks or registered trademarks of TIBCO Software Inc. and/or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.

The foregoing document includes a description of certain planned future availability of TIBCO product(s) or product functionality. Such description and projected timing is provided for informational purposes only and is subject to change without notice.


Jim Baptiste Amy Groden-Morrison

Davies Murphy Group, Inc. TIBCO Software Inc.

(781) 418-2438 (617) 702-1710

SOURCE TIBCO Software Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TIBCO Spotfire and Integromics Partner on Development of Genomics Platform for Province of Andalusia
2. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
(Date:11/30/2015)... -- Partnership includes an MPP ... the u niversity , s Solid Drug ... cale - up through ... Africa , where licensees based anywhere in the world will have the right ... Africa , where licensees based anywhere in the world will have ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):